[1] DE-YAN HOU. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.[J]. Cancer research, 2007, 67 2: 792-801. DOI:
10.1158/0008-5472.can-06-2925[2] HATEM SOLIMAN Scott A Melanie Mediavilla Varela. Indoleamine 2,3-dioxygenase: is it an immune suppressor[J]. Cancer journal, 2010, 16 4: 354-359. DOI:
10.1097/ppo.0b013e3181eb3343[3] MARIA FRIBERG. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection[J]. International Journal of Cancer, 2002, 101 2: 151-155. DOI:
10.1002/ijc.10645[4] RICHARD METZ. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.[J]. Oncoimmunology, 2012, 1 9: 1460-1468. DOI:
10.4161/onci.21716